Blanca Baez in an interview with US magazine CIO Applications on how to make unbiased clinical development and portfolio decisions with MH Predict.
Clinicians & hospitals
Create a precision medicine
center of excellence
Data can change how your organization approaches healthcare. Improve clinical decisions by harnessing molecular data – and become a key player in precision medicine.
Pharma & Biotech
Improve the prediction of drug
outcomes and pick the winners
With increasing health issues all over the world and the need for faster and cheaper drug development, it is necessary to start leveraging the vast data ocean of life sciences. Bringing together AI with predictive analytics and real-world data (RWD) is where it might be game changing: Predicting the success of clinical trials can redirect the focus of pharma and biotech companies onto compounds with the most potential, bringing drugs faster to the patients who need them.
Strongly mutated tumors are more likely to generate neoantigens that are recognized as foreign by immune cells. Tumors with a high TMB can therefore have a high immunogenicity.
Gaining insights has never been easier
Dataome has become one of the largest globally available resources of clinico-molecular data and knowledge. From millions of patient lives to hundreds of billions of molecular data points, it provides a single point of access to the world’s biomedical knowledge through our decision support applications.
Molecular Health Predict (MH Predict) is an application to predict clinical trials probabilities of success. It enables the improvement of clinical trial success and reduces clinical trial failure while optimizing resource allocation for the biopharma industry and investors and enhancing the overall efficiency of drug development.
Molecular Health Guide Mendel (MH Mendel) supports human geneticists in diagnosing hereditary diseases and creating diagnostic reports for individuals. The germline data analysis follows official genetic guidelines and uses the latest, world known ACMG variant classification criteria.
Molecular Health Guide (MH Guide) identifies safe and effective medication for cancer patients by analyzing the cancer’s molecular profile. It matches detected tumor mutations to the world’s knowledge in the field of oncology and helps medical experts to create a patient-specific clinical report with treatment recommendations.
Molecular Health Guide BRCA (MH BRCA) supports medical professionals in identifying and reporting clinically significant germline variants for hereditary breast and ovarian cancer. It creates individual patient reports based on NGS data from BRCA1/BRCA2 and other associated genes following official genetic guidelines.
You’re in good company
Molecular Health’s growing number of customers and partnerships include some of the best hospitals, laboratories, universities, and genetic facilities in the world.
Let’s talk about how our products can work for you
Call us for a product demo and to calculate the Return on Investment you can expect.
Phone: +1 346-221-1955